- Home
- DRUG vs EMX Comparison
DRUG vs EMX Comparison
Compare DRUG & EMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- EMX
- Stock Information
- Founded
- DRUG 2019
- EMX N/A
- Country
- DRUG United States
- EMX Canada
- Employees
- DRUG N/A
- EMX N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- EMX
- Sector
- DRUG Health Care
- EMX
- Exchange
- DRUG Nasdaq
- EMX Nasdaq
- Market Cap
- DRUG 345.6M
- EMX 338.0M
- IPO Year
- DRUG N/A
- EMX N/A
- Fundamental
- Price
- DRUG $45.43
- EMX $4.02
- Analyst Decision
- DRUG Strong Buy
- EMX Strong Buy
- Analyst Count
- DRUG 9
- EMX 2
- Target Price
- DRUG $81.67
- EMX $5.38
- AVG Volume (30 Days)
- DRUG 70.6K
- EMX 1.0M
- Earning Date
- DRUG 08-11-2025
- EMX 11-06-2025
- Dividend Yield
- DRUG N/A
- EMX N/A
- EPS Growth
- DRUG N/A
- EMX N/A
- EPS
- DRUG N/A
- EMX 0.04
- Revenue
- DRUG N/A
- EMX $29,864,000.00
- Revenue This Year
- DRUG N/A
- EMX $11.08
- Revenue Next Year
- DRUG N/A
- EMX $3.72
- P/E Ratio
- DRUG N/A
- EMX $94.07
- Revenue Growth
- DRUG N/A
- EMX N/A
- 52 Week Low
- DRUG $0.94
- EMX $1.65
- 52 Week High
- DRUG $79.02
- EMX $4.44
- Technical
- Relative Strength Index (RSI)
- DRUG 57.15
- EMX 53.59
- Support Level
- DRUG $39.70
- EMX N/A
- Resistance Level
- DRUG $49.49
- EMX $4.25
- Average True Range (ATR)
- DRUG 3.14
- EMX 0.18
- MACD
- DRUG 0.13
- EMX -0.14
- Stochastic Oscillator
- DRUG 64.66
- EMX 90.54
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.